Amylyx Pharmaceuticals, Inc. — Earnings Quality Grade F
AMLX · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
Insufficient data
AR growth -80.3% vs revenue growth -100.0%
Revenue -100.0%, CFFO 26.4%. Cash follows revenue
Expense Quality
No material inventory
CapEx growth -12.1% vs revenue -100.0%. Normal
Insufficient data
Gross margin swung -136.0pp (93.3% → -42.6%)
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.1B)
Accruals ratio = -6.4%. Low accruals
Cash $0.3B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -0.0x. Healthy
Other assets grew 136.9% vs revenue -100.0%
No write-off data
Acquisition Risk
FCF after acquisitions negative for 2/3 years
No goodwill
Manipulation Score
Calculation error: float division by zero
Portfolio monitoring
Monitor AMLX continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25